A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage
NCT ID: NCT00168896
Last Updated: 2006-02-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
286 participants
INTERVENTIONAL
2001-10-31
2006-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The combination chemotherapies for this study are Carboplatin plus Irinotecan versus Carboplatin plus Etoposide.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Carboplatin plus Irinotecan vs Carboplatin plus Etoposide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* no prior chemotherapy
* measurable tumor disease
* karnofsky performance 70
Exclusion Criteria
* NYHA III
* chronic diarrhea, obstructive bowel syndrome
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Aventis Pharmaceuticals
INDUSTRY
Charite University, Berlin, Germany
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ulrich Keilholz, MD
Role: PRINCIPAL_INVESTIGATOR
Charité Campus Benjamin Franklin University Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hematology & Oncology Charité CBF Berlin, Germany
Berlin, State of Berlin, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Haema CBF SCLC UK/AS 01
Identifier Type: -
Identifier Source: org_study_id